Verified research on prevention, screening, diagnostics, and early detection — evidence stage, regulatory status, and guideline status are always shown as separate, independent facts, never collapsed into a single recommendation.
This page groups verified research on prevention, screening, diagnostics, and early detection. It describes research and evidence status — not a personal screening recommendation. Talk to a qualified clinician about what applies to your own situation.
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
No verified stories in this category yet.
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV…
Primary source cited
Last reviewed
In the prospective, 20,176-participant BLUE-C study, Cologuard Plus (a next-generation multitarget stool DNA test) detected colorectal cancer with 95% sensitivity and correctly identified 94% of participants without colorectal cancer or…
Primary source cited
Last reviewed
Across two validation cohorts, an 18-gene urine test (MPS2) substantially outperformed PSA alone (AUC 0.81–0.82 vs. 0.60) for detecting higher-grade prostate cancer, with modeled reductions in unnecessary biopsies, including in…
Primary source cited
Last reviewed
No verified stories in this category yet.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.